Now I have enough to write a comprehensive preview. Let me pull the key numbers together and draft the report.# IDEXX Laboratories (IDXX) — Q2 2026 Earnings Preview Report Date: August 4, 2026 (before market open) | Event: 2026Q2 Earnings Call
| Stock price (8/3/26 close) | ~$568 |
| 2026 YTD | Down from a ~$725 high in mid-January to ~$568 (roughly -15% YTD, -21% off highs) |
| Consensus Q2 Revenue | ~$1.20B (+8.3% y/y) |
| Consensus Q2 EPS | ~$3.95 (+8.8% y/y, vs. $3.63 in Q2 2025) |
| Beat history | Beat consensus EPS in each of the last four quarters, average surprise ~6% |
| Sell-side stance | "Moderate Buy" — 8 Strong Buy / 1 Moderate Buy / 6 Hold among 15 analysts; average price target ~$721, implying meaningful upside from current levels |
| Next catalyst after earnings | 2026 Investor Day on August 13, 2026 in Westbrook, ME — first strategy showcase under new CEO Mike Erickson, expected to detail AI roadmap |
IDEXX enters this print off a very strong Q1 2026. The company delivered revenue growth of 14% as reported and 11% organically, supported by over 11% organic growth in CAG Diagnostics recurring revenues, and posted earnings per share of $3.47 in the quarter, resulting in EPS growth of 15% on a comparable basis. Management used that beat to raise full-year guidance, moving the full year revenue range to between $4.675 billion to $4.760 billion... an outlook for overall reported revenue growth of 8.6% to 10.6%, with an updated full year overall organic revenue growth outlook... for 7.7% to 9.7% with an organic CAG Diagnostic recurring revenue growth of 8.7% to 10.7%, and an updated full year EPS outlook to $14.45 to $14.90 per share.
Importantly, management also pre-guided Q2 specifically on the Q1 call: "we're planning for reported revenue growth of 7.3% to 9.3%, including approximately 60 basis point growth benefit from foreign exchange impacts... an overall organic revenue growth range of 6.7% to 8.7% and CAG Diagnostics recurring revenue growth of 8.5% to 10.5%." They also flagged a negative 50 basis point impact from equivalent days in the second quarter and guided second quarter reported operating margins... to be 33.9% to 34.3%, reflecting expansion of 10 to 50 basis points on a comparable basis, as we expect increased spending during Q2 related to timing of projects. That step-down in margin expansion cadence (vs. Q1's +100bps comparable) is one area investors will watch closely — is it just spend timing, or a sign of moderating operating leverage?
1. U.S. clinical visit trends and "green shoots." Q1 showed U.S. same-store clinical visits declined minus 1% in the quarter, better than plan, with management noting continued positive momentum from the aging pet population, pets that are 5-plus years and older and a trailing 12-month average... very similar to what we're anticipating for the full year, which is about minus 1.5% decline in clinical visits. Independent industry data still show ongoing pressure — Vetsource data cited a "3.1 percent drop in 2025" in overall visits — so any incremental deterioration or improvement in wellness vs. non-well visit mix will be a swing factor for the stock.
2. CAG Diagnostics recurring revenue pricing/volume mix. Q1 organic growth of 11% included roughly a 4% global net price benefit with the rest volume-driven; guidance embeds no incremental pricing change, so watch whether volume trends (installed base growth, utilization/diagnostic frequency per visit) hold up.
3. InVue Dx placement pace toward the 5,500 full-year target. Q1 placements were 1,100 units, and on the call analysts pushed on pacing given a strong prior-year comp; management reiterated confidence in the full-year target. Q2 placement numbers and installed-base growth (up 12% y/y exiting Q1) will be a key data point, along with progress on the controlled-to-unconstrained rollout of the Fine Needle Aspiration (F&A) menu expansion, which management said would broaden through Q2 with a full volume ramp expected in the second half.
4. Cancer Dx and Reference Lab momentum. Cancer Dx had reached over 7,500 ordering practices by Q1 and had just launched internationally in Europe and Australia — watch for updated adoption metrics and commentary on the next test addition (mast cell detection later this year, a third test by year-end).
5. Rapid Assay drag and Catalyst cannibalization. Rapid Assay revenue was flat organically in Q1 due to customers shifting pancreatic lipase testing onto the Catalyst platform; this mix shift should persist into Q2.
6. Second-half comp dynamics. On the Q1 call, an analyst noted that the implied first-half CAG Diagnostics recurring growth (~10.25%) sits above the full-year midpoint guide (~9.7%), given tougher year-over-year comps in H2. Management's response leaned on continued commercial execution, innovation contribution (inVue Dx, Catalyst menu additions) and Reference Lab momentum rather than an assumed visit-trend improvement — worth revisiting given Q2 is typically the seasonally strongest quarter.
7. New CEO's first quarter fully in the seat. Mike Erickson officially became CEO around the May 12 annual meeting (Jay Mazelsky transitioned to Executive Chair). This is his first full quarter leading the company and first earnings call as CEO — tone, priorities (Erickson flagged AI, commercial reach expansion, and Diagnostics/Software integration as top focuses) and any strategic framing ahead of the Investor Day will be scrutinized.
8. FX and macro puts/takes. Q2 guidance embeds a ~60bp FX tailwind to revenue growth; the dollar's path, plus any updates on tariff impacts, Middle East-related Water segment supply-chain disruption (flagged in Q1), and consumer/fuel-price sensitivity affecting discretionary wellness visits are all worth monitoring in prepared remarks and Q&A.
9. Capital allocation. IDEXX repurchased $361 million of stock in Q1 (605k shares, ~2.1% y/y reduction in diluted share count) while running low leverage (0.6x gross/0.5x net). Watch for continuation of buyback pace and any change to the 85–95% free-cash-flow-to-net-income conversion target.
IDXX shares have been notably weak relative to fundamentals — the stock is down meaningfully from its 2026 high near $725 (mid-January) to the high-$500s heading into this report, despite the Q1 beat-and-raise. Barchart's analyst survey characterized sentiment as "reasonably bullish" with a "Moderate Buy" consensus and noted the stock has underperformed as investors worried about slowing companion-animal growth and post-pandemic demand normalization, compounded by FX headwinds. A Zacks Earnings ESP of 0.00% (i.e., no directional bias baked into the "most accurate" estimate vs. consensus) suggests the market isn't leaning hard toward a beat or miss this quarter — a contrast to IDEXX's historical beat pattern.
The setup into Q2 is one of solid guided growth (high-single-digit organic revenue, low-double-digit CAG Dx recurring growth) against a valuation that has already de-rated on visit-trend and macro anxiety, even as the company keeps beating and raising. Key swing factors for the print: (1) confirmation that the "green shoots" in older-pet visit trends and non-well visits are sustaining into Q2, (2) InVue Dx/F&A placement and utilization cadence staying on track for the 5,500-unit full-year target, (3) margin performance given the guided deceleration in comparable operating margin expansion, and (4) any strategic signaling from new CEO Mike Erickson ahead of the August 13 Investor Day, where AI strategy and the long-term growth algorithm are expected to be a central topic.